Copyright © Inderes 2011 - present. All rights reserved.

Lytix Biopharma

Less than 1K followers

LYTIX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.

Read more
Market cap
-
Turnover
-
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
14.4
2026

General meeting '26

21.5
2026

Interim report Q1'26

27.8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.